News | January 03, 2024
WuXi XDC partners with IntoCell to accelerate ADC discovery and development
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Sirius JV will be owned 51% by Sirius and 49% by Adani
Karkinos Healthcare has demonstrated exceptional dedication to privacy, setting a commendable example for businesses navigating the complexities of the digital landscape
NEIAFMR to be developed as the national hub for folk medicine
Furthering cell therapy ambition across oncology and autoimmune diseases
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Ami Organics will also sign an MoU with Government of Gujarat for investment amounting up to Rs 300 crores for set up of dedicated manufacturing facility for electrolytes business
NPPA fixes the ceiling price of scheduled formulations as per the extant provisions of DPCO, 201
Subscribe To Our Newsletter & Stay Updated
